


CLAIMS

1. A monoclonal antibody that binds a KIR3DL2 polypeptide, wherein said antibody comprises human heavy and light chain variable region framework sequences, wherein the heavy chain framework comprises a glutamine at residue 39 and the light chain framework comprises a glutamine at residue 38 (Abnum numbering).
2. The antibody of claim 1, wherein the reference antibody comprises constant regions of human IgG isotype.
3. The antibody of claims 1-2, wherein said antibody detectably reduces (or eliminates) binding between the KIR3DL2 and a HLA natural ligand of KIR3DL2.
4. The antibody of claims 1-3, wherein said antibody binds: (a) a KIR3DL2 polypeptide allele_*001, (b) a KIR3DL2 polypeptide allele_*002, and (c) a KIR3DL2 polypeptide allele_*007, in each case wherein the KIR3DL2 polypeptide is expressed on the surface of a cell.
5. The antibody of any one of the above claims, wherein said antibody has reduced binding to a mutant KIR3DL2 polypeptide having amino acid mutations I60N and G62S, relative to binding between the antibody and a wild-type KIR3DL2 polypeptide of SEQ ID NO: 1.
6. The antibody of any one of the above claims, wherein said antibody has reduced binding to a mutant KIR3DL2 polypeptide having amino acid mutations R13W, A25T and Q27R, relative to binding between the antibody and a wild-type KIR3DL2 polypeptide of SEQ ID NO: 1.
7. The antibody of any one of the above claims, wherein said antibody has reduced binding to a mutant KIR3DL2 polypeptide having amino acid mutations P14S, S15A and H23S, relative to binding between the antibody and a wild-type KIR3DL2 polypeptide of SEQ ID NO: 1.
8. The antibody of any one of the above claims, wherein said antibody is not internalized when bound to KIR3DL2-expressing cells.
9. The antibody of claims 1-8, wherein said antibody detectably reduces binding between the KIR3DL2 and HLA-B27.

10. The antibody of claims 1-9, wherein said antibody does not substantially bind to a KIR3DL1 polypeptide.
11. The antibody of any one of the above claims, wherein said antibody competes for binding to a KIR3DL2 polypeptide with an antibody selected from the group consisting of:
- (a) an antibody comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 31 and 25 (2B12), and
 - (b) an antibody comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 14 and 9 (10G5).
12. The antibody any one of the above claims, wherein said antibody comprises (i) a heavy chain comprising CDRs 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO: 2 (HCDR1), SEQ ID NO: 3 (HCDR2) and SEQ ID NO: 4 (HCDR3) respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO: 5, 6 or 7, respectively.
13. The antibody any one of the above claims, wherein said antibody comprises (i) a heavy chain comprising CDRs 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising a sequence of SEQ ID NO: 18 (HCDR1), SEQ ID NO: 19 (HCDR2) and SEQ ID NO: 20 (HCDR3) respectively, and (ii) a light chain comprising CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising a sequence of SEQ ID NO: 21, 22 or 23, respectively.
14. An antibody that binds to a KIR3DL2 polypeptide, comprising:
- (a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of 10G5-H0, -H1, -H2, -H3, -H4, -H5 and -H6; and
 - (b) a light chain variable region comprising an amino acid sequence selected from the group consisting of 10G5-L0, -L1, -L2, -L3, -L4 and -L5.
15. An antibody that binds to a KIR3DL2 polypeptide, comprising:
- (a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of 2B12-H0, -H1, -H2, -H3 and -H4; and
 - (b) a light chain variable region comprising an amino acid sequence selected from the group consisting of 2B12-L0, -L1, -L2, -L3 and -L4.
16. An antibody that binds to a KIR3DL2 polypeptide, selected from the group consisting of:

- (a) an antibody comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 31 and 25, and
 - (b) an antibody comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 31 and 26.
17. An antibody that binds to a KIR3DL2 polypeptide selected from the group consisting of:
- (a) an antibody comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 14 and 9, and
 - (b) an antibody comprising respectively a VH and VL region comprising the amino acid sequence of SEQ ID NOS: 15 and 9.
18. The antibody of any one of the above claims, wherein said antibody has bivalent binding affinity (K_D) for a human KIR3DL2 polypeptide at of less than 10^{-8} M.
19. The antibody of any one of the above claims, wherein the antibody is a full length antibody comprising a heavy chain variable region (VH) fused to a human gamma 1 constant region and a light chain variable region (VL) fused to a human kappa constant region.
20. The antibody of any one of the above claims, wherein said antibody comprises a human heavy chain constant region comprising amino acid substitution(s) that increase binding to a human FcγIIIA (CD16) receptor.
21. A pharmaceutical composition comprising an antibody according to any one of the above claims, and a pharmaceutically acceptable carrier.
22. The formulation of claim 21 comprising: (a) about 0.05 mg/mL to about 10 mg/mL of an antibody according to any one of claims 1-20; (b) buffer system; and (c) isotonic agent, at a pH of between 6.5 and 8.
23. The composition of claim 22, wherein the pH is about 7.4.
24. A method for the treatment or prevention of disease in a patient in need thereof, the method comprising administering to said patient an effective amount of an antibody of claims 1-20 or a composition of claims 21-23.

25. The method of claim 24, wherein said disease is a peripheral T cell lymphoma.
 26. The method of claim 24, wherein said cancer is selected from Mycosis fungoides and Sezary Syndrome.
 27. The method of claim 24, wherein said disease is an inflammatory or autoimmune disorder.
- 

CLAIMS

1. An antibody or antibody fragment that binds a KIR3DL2 polypeptide, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 31; and
 - 5 (b) a light chain variable region comprising an amino acid sequence of SEQ ID NOs: 25 or 26.
2. An antibody according to Claim 1, in which the antibody is a full length antibody comprising a heavy chain variable region (VH) fused to a human gamma 1 constant region and a light chain variable region (VL) fused to a human kappa constant region.
- 10 3. An antibody according to any preceding claim, in which the antibody comprises a human heavy chain constant region comprising amino acid substitution(s) that increase binding to a human FcγIIIa (CD16) receptor.
4. A pharmaceutical composition comprising an antibody or antibody fragment according to any preceding claim, and a pharmaceutically acceptable carrier.
- 15 5. A formulation according to Claim 4 comprising: (a) about 0.05 mg/mL to about 10 mg/mL of an antibody according to any of Claims 1, 2 or 3; (b) buffer system; and (c) isotonic agent, at a pH of between 6.5 and 8.
6. A composition according to any preceding claim, for use in the treatment or prevention of disease in a patient in need thereof.
- 20 7. A method according to Claim 6, in which the disease is a peripheral T cell lymphoma.
8. A method according to Claim 7, in which the cancer is selected from Mycosis fungoides and Sezary Syndrome.
9. A recombinant nucleic acid encoding an antibody or antibody fragment according to any of Claims 1, 2 or 3.
- 25 10. A host cell comprising a nucleic acid according to Claim 9.